AU2013290274A1 - Laquinimod formulations without alkalizing agent - Google Patents
Laquinimod formulations without alkalizing agent Download PDFInfo
- Publication number
- AU2013290274A1 AU2013290274A1 AU2013290274A AU2013290274A AU2013290274A1 AU 2013290274 A1 AU2013290274 A1 AU 2013290274A1 AU 2013290274 A AU2013290274 A AU 2013290274A AU 2013290274 A AU2013290274 A AU 2013290274A AU 2013290274 A1 AU2013290274 A1 AU 2013290274A1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- stable pharmaceutical
- laquinimod
- filler
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670268P | 2012-07-11 | 2012-07-11 | |
| US61/670,268 | 2012-07-11 | ||
| PCT/US2013/049894 WO2014011750A1 (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013290274A1 true AU2013290274A1 (en) | 2014-11-27 |
Family
ID=49914501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013290274A Abandoned AU2013290274A1 (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140018386A1 (enExample) |
| EP (1) | EP2872141A4 (enExample) |
| JP (1) | JP2015527321A (enExample) |
| KR (1) | KR20150036553A (enExample) |
| CN (1) | CN104470519A (enExample) |
| AR (1) | AR091706A1 (enExample) |
| AU (1) | AU2013290274A1 (enExample) |
| BR (1) | BR112015000321A2 (enExample) |
| CA (1) | CA2873230A1 (enExample) |
| EA (1) | EA201590193A1 (enExample) |
| HK (1) | HK1209054A1 (enExample) |
| IL (1) | IL236229A0 (enExample) |
| MX (1) | MX2015000398A (enExample) |
| NZ (1) | NZ630241A (enExample) |
| SG (2) | SG11201407688QA (enExample) |
| TW (1) | TW201408299A (enExample) |
| UA (1) | UA115555C2 (enExample) |
| WO (1) | WO2014011750A1 (enExample) |
| ZA (1) | ZA201500287B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2682120B1 (en) | 2007-12-20 | 2016-08-03 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| AU2014236232A1 (en) | 2013-03-14 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| JP2017514824A (ja) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド |
| CN107823150A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种可快速分散的片剂及其制备方法 |
| CN107823168A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种快速溶解的片剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| PT1937642E (pt) * | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
| NZ573846A (en) * | 2006-06-12 | 2012-01-12 | Teva Pharma | Stable laquinimod preparations |
| EP2682120B1 (en) * | 2007-12-20 | 2016-08-03 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| WO2013016686A1 (en) * | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
-
2013
- 2013-07-08 AR ARP130102429 patent/AR091706A1/es unknown
- 2013-07-09 TW TW102124610A patent/TW201408299A/zh unknown
- 2013-07-10 SG SG11201407688QA patent/SG11201407688QA/en unknown
- 2013-07-10 NZ NZ630241A patent/NZ630241A/en not_active IP Right Cessation
- 2013-07-10 KR KR1020157003693A patent/KR20150036553A/ko not_active Withdrawn
- 2013-07-10 AU AU2013290274A patent/AU2013290274A1/en not_active Abandoned
- 2013-07-10 HK HK15109818.4A patent/HK1209054A1/xx unknown
- 2013-07-10 BR BR112015000321A patent/BR112015000321A2/pt active Search and Examination
- 2013-07-10 SG SG10201700198VA patent/SG10201700198VA/en unknown
- 2013-07-10 WO PCT/US2013/049894 patent/WO2014011750A1/en not_active Ceased
- 2013-07-10 CA CA2873230A patent/CA2873230A1/en not_active Abandoned
- 2013-07-10 EP EP13816725.9A patent/EP2872141A4/en not_active Withdrawn
- 2013-07-10 CN CN201380027660.2A patent/CN104470519A/zh active Pending
- 2013-07-10 JP JP2015521771A patent/JP2015527321A/ja active Pending
- 2013-07-10 MX MX2015000398A patent/MX2015000398A/es unknown
- 2013-07-10 EA EA201590193A patent/EA201590193A1/ru unknown
- 2013-07-10 US US13/938,733 patent/US20140018386A1/en not_active Abandoned
- 2013-10-07 UA UAA201413984A patent/UA115555C2/uk unknown
-
2014
- 2014-12-14 IL IL236229A patent/IL236229A0/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00287A patent/ZA201500287B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2872141A4 (en) | 2016-01-13 |
| KR20150036553A (ko) | 2015-04-07 |
| AR091706A1 (es) | 2015-02-25 |
| ZA201500287B (en) | 2016-10-26 |
| NZ630241A (en) | 2017-09-29 |
| BR112015000321A2 (pt) | 2017-06-27 |
| WO2014011750A8 (en) | 2014-12-04 |
| SG10201700198VA (en) | 2017-02-27 |
| MX2015000398A (es) | 2015-04-10 |
| EA201590193A1 (ru) | 2015-04-30 |
| CN104470519A (zh) | 2015-03-25 |
| WO2014011750A1 (en) | 2014-01-16 |
| US20140018386A1 (en) | 2014-01-16 |
| CA2873230A1 (en) | 2014-01-16 |
| TW201408299A (zh) | 2014-03-01 |
| IL236229A0 (en) | 2015-01-29 |
| UA115555C2 (uk) | 2017-11-27 |
| SG11201407688QA (en) | 2014-12-30 |
| HK1209054A1 (zh) | 2016-03-24 |
| JP2015527321A (ja) | 2015-09-17 |
| EP2872141A1 (en) | 2015-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2013290274A1 (en) | Laquinimod formulations without alkalizing agent | |
| JP5514249B2 (ja) | 抗痴呆薬の安定化方法 | |
| US20230285386A1 (en) | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS | |
| US6752997B2 (en) | Process for preparing non-hygroscopic sodium valproate composition | |
| KR20200061244A (ko) | 바레니클린 유리염기를 포함하는 서방성 제제 및 이를 제조하는 방법 | |
| US20080038332A1 (en) | Stable pharmaceutical formulation comprising atorvastatin calcium | |
| HU225779B1 (en) | Pharmaceutical composition containing paracetamol and drotaverine and process for producing it | |
| AU2013250251B2 (en) | Encapsulated formulation | |
| EP4164616A1 (en) | Oral formulation comprising a crystalline form of rabeximod | |
| KR101609105B1 (ko) | 용출성 및/또는 흡수성이 개선된 경구 투여용 의약 조성물 | |
| JPWO2007049626A1 (ja) | カベルゴリン含有経口固形製剤 | |
| WO2023062647A1 (en) | Pomalidomide formulation | |
| US20200323780A1 (en) | Bilayer combination tablet for oral administration containing tramadol and celecoxib | |
| AU2002241960A1 (en) | Process for preparing non-hygroscopic sodium valproate composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |